NCT06938490

Brief Summary

This study is a randomized, controlled trial comparing the short- and long-term outcomes of left colonic artery or first sigmoid artery preservation for rectal surgery. Eligible patients will be randomized to D3-lymphodissection with preservation of the first sigmoid artery or left colonic artery in a 1:1 ratio according to a computer-generated randomization list created in advance (includes removal of 252, 253 l/u groups, 241 groups of distal sigmoid colon sites when the neoplasm is highly located). The operation involves removal of the tumor with oncologically adequate clearance, adherence to the principles of operation in embryonic layers. The criterion for performing D3-lymphodissection is visualization of the site of the inferior mesenteric artery (IMA) branching from the aorta. During the surgical intervention, l/u groups 252 and 253 are elevated along the superior rectus artery, the NBA is skeletonized circularly so that there are no l/u and no visible areas of fatty tissue. In the group with preservation of the left colonic artery, the NBA is isolated, clipped and crossed immediately after the LCA, and in the group with preservation of the first SA, the NBA is skeletonized to the level of the first sigmoid artery, clipped and crossed immediately after the first sigmoid artery . After the intestinal resection stage, a colorectal anastomosis is formed, information on drain placement. The primary endpoint is to assess the incidence of IA - communication of the intraluminal compartment of the intestine with the extraluminal compartment, anastomosis leakage in the area of the formed anastomosis - which will be performed at 30 days postoperatively and categorized according to the Clavien-Dindo scale. HA can be diagnosed by MRI, CT with proctography, endoscopic examination, or patient examination (if low anastomoses are formed). Any adverse event in the postoperative period is also classified according to the Clavien-Dindo scale and recorded in the individual patient's chart. Each patient will have an individual electronic record (eCRF open clinica.), where individual patient data will be entered and where the data obtained will be stored.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
778

participants targeted

Target at P75+ for not_applicable

Timeline
37mo left

Started Apr 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress27%
Apr 2025May 2029

First Submitted

Initial submission to the registry

March 26, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

April 1, 2025

Completed
21 days until next milestone

First Posted

Study publicly available on registry

April 22, 2025

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2029

Last Updated

April 22, 2025

Status Verified

March 1, 2025

Enrollment Period

3.1 years

First QC Date

March 26, 2025

Last Update Submit

April 14, 2025

Conditions

Keywords

Anastomotic leakageColorectal cancer (CRC)First sigmoid artery (SA)Left colonic artery (LCA)

Outcome Measures

Primary Outcomes (1)

  • Failure of colorectal anastomoses within 30 days of surgery

    The failure of colorectal anastomosis will be registered in the presence of clinical symptoms confirmed by rectal examination (with low anastomoses) and/or MRI

    3 years

Secondary Outcomes (5)

  • Assessment of radicality of surgery: number of LU removed

    3 years

  • Long-term results: overall and recurrence-free survival at 1 year, 3 and 5 years, respectively, the percentage of three- and five-year survival in the group where sigmoid artery preservation was performed and where it was clipped.

    3 years

  • Registration of all deviations from the normal course in the postoperative period

    3 years

  • Assessment of radicality of surgery: proximal and distal clearance

    3 years

  • Assessment of radicality of surgery: number of R1 resections

    3 years

Study Arms (2)

LCA preserved

ACTIVE COMPARATOR

A group of people with only the left colonic artery preserved

Procedure: Anterior rectal resection with D3-lymphatic dissection

First SA preserved

ACTIVE COMPARATOR

A group of people with only the first sigmoid artery preserved

Procedure: Anterior rectal resection with D3-lymphatic dissection

Interventions

This study aims to determine the incidence of anastomosis failure in the group with first SA and LCA preservation in order to identify the feasibility of manipulation. The study is unique in that there is only one study in the world that evaluates the incidence of anastomosis failure with preservation of the first sigmoid and there is no study comparing the groups described in this study.

First SA preservedLCA preserved

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent form
  • ECOG status is 0-2.
  • Age over 18 years
  • TNM stage according to version VIII T1b-4aN0-2M0 (M1 in case of resectable metastases confirmed by preoperative staging (colonoscopy, chest and abdominal CT).
  • Histologically confirmed adenocarcinoma of the colon, the proximal edge of which is not higher than or equal to 20 cm from the anus
  • Clinical indications for colorectal resection with anastomosis formation

You may not qualify if:

  • Medical or psychiatric reasons affecting the patient's decision to participate in the study
  • Pregnancy or breastfeeding
  • Medical conditions contraindicated for surgery
  • Synchronous or metachronous malignancies
  • Acute intestinal obstruction, bleeding or perforation
  • Preplanned obstructive bowel resection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beloostrov Clinic High Tech

Saint Petersburg, Russia

Location

MeSH Terms

Conditions

Colorectal NeoplasmsNeoplasmsAnastomotic Leak

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Timur Lankov The head of the Department of Abdominal and Thoracic Oncology

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 26, 2025

First Posted

April 22, 2025

Study Start

April 1, 2025

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

May 1, 2029

Last Updated

April 22, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations